PMV PharmaceuticalsPMVP +3.48%34 Current Ratio is 11.14 as of Mar. 2026, which is 50% below its 10-year median of 22.30. GuruFocus rates PMVP with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, PMV Pharmaceuticals ranks better than 80.33% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. PMV Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 11.14.
PMV Pharmaceuticals has a current ratio of 11.14. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for PMV Pharmaceuticals's Current Ratio or its related term are showing as below:
PMVP'
s Current Ratio Range Over the Past 10 Years
Min: 10.09 Med: 22.3 Max: 68.24
Current: 11.14
During the past 8 years, PMV Pharmaceuticals's highest Current Ratio was 68.24. The lowest was 10.09. And the median was 22.30.
PMVP's Current Ratio is ranked better than 80.33% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs PMVP: 11.14
PMV Pharmaceuticals (NAS:PMVP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
PMV Pharmaceuticals Current Ratio Related Terms
PMV Pharmaceuticals Current Ratio Historical Data
* Premium members only.
The historical data trend for PMV Pharmaceuticals's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMVP vs MNOV, TCRX, BSEM: Current Ratio Comparison
For the Biotechnology subindustry, PMV Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PMV Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where PMV Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMV Pharmaceuticals (PMVP) has a Current Ratio of 11.14 as of Mar. 2026. This is 50% below median its historical median of 22.30. Over the past decade, PMV Pharmaceuticals' Current Ratio has ranged from 10.09 to 68.24. According to the industry distribution chart, PMV Pharmaceuticals ranks #278 out of 1413 companies in the Biotechnology industry, placing it in the top 19.7%.
Is PMV Pharmaceuticals' Current Ratio too high?
PMV Pharmaceuticals' current Current Ratio of 11.14 is 50% below median its 10-year median of 22.30. Over the past 10 years, this metric has ranged from a low of 10.09 to a high of 68.24. The Biotechnology industry median Current Ratio is 3.89. PMV Pharmaceuticals' value of 11.14 is 186.4% above this industry median. Based on the distribution chart, PMV Pharmaceuticals ranks #278 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PMV Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does PMV Pharmaceuticals' Current Ratio compare to MNOV and TCRX?
According to the Biotechnology industry distribution chart, PMV Pharmaceuticals ranks #278 out of 1413 companies for Current Ratio. This places PMV Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. PMV Pharmaceuticals' value of 11.14 is 186.4% above this benchmark. Historically, PMV Pharmaceuticals' own Current Ratio has ranged from 10.09 to 68.24 over the past decade. While the company's 10-year median is 22.30 vs. the industry median of 3.89, PMV Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PMV Pharmaceuticals's current Current Ratio of 11.14 is 186.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PMV Pharmaceuticals's current Current Ratio is 11.14, which is 50% below median its own 10-year median of 22.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PMV Pharmaceuticals stock overvalued right now?
PMV Pharmaceuticals (PMVP) has a current Current Ratio of 11.14. The current Current Ratio is 11.14, which is 50% below median its 10-year median of 22.30 and 186.4% above the Biotechnology industry median of 3.89. PMV Pharmaceuticals' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For PMV Pharmaceuticals (PMVP), the current Current Ratio is 11.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
34GF Score
Get the complete analysis for PMVP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMVP has been successfully added to your 
